News

Mylan, Roche reach deal over cancer drug

BY Alaric DeArment

PITTSBURGH — Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.

Mylan announced Wednesday that it had entered a settlement and license agreement with Hoffmann La Roche resolving a patent infringement lawsuit over Xeloda (capecitabine) tablets, a drug used to treat breast and colorectal cancers that have spread to other parts of the body.

The litigation was dismissed Tuesday, though additional details of the deal were not disclosed, and it is still subject to review by the Department of Justice and the Federal Trade Commission.

Xeloda had sales of $570 million during the 12-month period ended in June, according to IMS Health.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Pfizer moves forward in Icagen acquisition deal

BY Alaric DeArment

NEW YORK — The offering period for Pfizer’s acquisition of Icagen has expired, allowing the former to purchase more than 5 million shares in the company, Pfizer said.

Pfizer said that as of Monday, 5.4 million shares of Icagen had been put up for sale. Along with the 1.1 million shares Pfizer already owns, this would give it control of 70.2% of Icagen, which develops drugs for pain and other conditions. Pfizer plans to acquire the remaining shares as well.

Pfizer and Icagen announced in July a deal whereby Pfizer would acquire all the remaining 8.3 million shares of Icagen for $56 million, or $6 per share.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Rimmel London unveils new makeup for spring

BY Antoinette Alexander

NEW YORK — Coty’s Rimmel London brand is gearing up for spring with an array of new makeup for eyes and face, including its new ScandalEyes mascara for fuller, outrageously exaggerated lashes.

This season, the hottest beauty look out of London is bright, emphasized eyes offset by a natural flush. With high-impact shadow shades, precision liner, ultra-plumping mascara and custom cheek color, Rimmel London is aiming to help beauty mavens get noticed this spring.

New products include:

  • Volume Flash ScandalEyes mascara: The mascara is made with a blend featuring triple the collagen and keratin of other mascaras on the market, and has a flexible MaxDensity brush that’s longer, wider, denser and 50% bigger than Rimmel’s biggest brush. The price is $6.99

  • Glam’Eyes HD eyeshadow: The bold, dual-use shadows work wet or dry, allowing you to customize the color. The shadows promise to last up to 10 hours. Shades include, but are not limited to, English Oak, Purple Reign and Green Park. The price is $5.99.

  • Match Perfection 3 Tone blush: Featuring three shades in one, Match Perfection 3 Tone Blush features smart-tone technology that adapts to skin tone and blue sapphire pigments for true-to-you color. The blendable formula makes harsh lines a thing of the past. The price is $4.97 at Walmart.

  • Exaggerate eyeliner: This liquid liner features an ultra-fine felt tip designed to absorb maximum liquid liner and deposit intense pigment for bold, exact application. The formula is made with moisturizing sorbitol and glycerin. The price is $6.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?